Two types of anti-TL (thymus leukemia) CTL clones with distinct target specificities: differences in cytotoxic mechanisms and accessory molecule requirements
- PMID: 9605121
Two types of anti-TL (thymus leukemia) CTL clones with distinct target specificities: differences in cytotoxic mechanisms and accessory molecule requirements
Abstract
TCRalphabeta CTL clones recognizing mouse thymus leukemia (TL) Ags were established and categorized into two groups: those killing any TL+ target cells (type I) and those killing only TL+ Con A blasts (type II). Cold target inhibition assays showed that the antigenic determinant(s) recognized by type II clones are expressed not only on TL+ Con A blasts but also on other TL+ target cells. The relation of the target specificity to the killing machinery and the accessory molecules involved in cytotoxicity were therefore analyzed using four representative clones selected from each type. Of the target cells tested, Fas was only expressed on Con A blasts, indicating that Fas ligand (FasL)-dependent cytotoxicity is limited to such cells. All four type II and one of four type I clones expressed FasL on the surface, while both types contained perforin in the cytoplasm. Blocking studies using neutralizing anti-FasL mAbs and concanamycin A (CMA), a selective inhibitor of the perforin pathway, suggested that type I clones kill target cells by way of perforin, while type II clones kill TL+ Con A blasts through FasL together with perforin. For their cytotoxicity, type I CTLs require a signal through CD8, while type II require LFA-1/ICAM-1 interactions. Type II clones also need a co-stimulatory signal through an unknown molecule for perforin-dependent cytotoxicity. These results taken together suggest that the difference in the target specificity of anti-TL CTL clones is due to variation in the killing machineries and the dependence on accessory molecules.
Similar articles
-
Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity.J Immunol. 1996 May 15;156(10):3678-86. J Immunol. 1996. PMID: 8621902
-
MRL/lpr CD4- CD8- and CD8+ T cells, respectively, mediate Fas-dependent and perforin cytotoxic pathways.Eur J Immunol. 1997 Feb;27(2):415-20. doi: 10.1002/eji.1830270211. Eur J Immunol. 1997. PMID: 9045912
-
CD2/LFA-3 or LFA-1/ICAM-1 but not CD28/B7 interactions can augment cytotoxicity by virus-specific CD8+ cytotoxic T lymphocytes.Eur J Immunol. 1993 Feb;23(2):418-24. doi: 10.1002/eji.1830230218. Eur J Immunol. 1993. PMID: 7679643
-
Fas- and perforin-independent mechanism of cytotoxic T lymphocyte.Immunol Res. 1998;17(1-2):89-93. doi: 10.1007/BF02786434. Immunol Res. 1998. PMID: 9479571 Review.
-
Anti-T3 antibody both activates and inhibits the cytotoxic activity of human T cell clones.Behring Inst Mitt. 1985 Aug;(77):30-8. Behring Inst Mitt. 1985. PMID: 3936472 Review.
Cited by
-
Immunity against mouse thymus-leukemia antigen (TL) protects against development of lymphomas induced by a chemical carcinogen, N-butyl-N-nitrosourea.Cancer Sci. 2004 Nov;95(11):914-9. doi: 10.1111/j.1349-7006.2004.tb02202.x. Cancer Sci. 2004. PMID: 15546510 Free PMC article.
-
Studies of the mechanism of cytolysis by tumour-infiltrating lymphocytes.Clin Exp Immunol. 1999 Jun;116(3):388-94. doi: 10.1046/j.1365-2249.1999.00879.x. Clin Exp Immunol. 1999. PMID: 10361224 Free PMC article.
-
Thymus-leukemia antigen (TL) as a major histocompatibility complex (MHC) class Ib molecule and tumor-specific antigen.Cancer Sci. 2004 Jun;95(6):469-74. doi: 10.1111/j.1349-7006.2004.tb03234.x. Cancer Sci. 2004. PMID: 15182425 Free PMC article. Review.
-
Expression and function of synaptotagmin VII in CTLs.J Immunol. 2007 Feb 1;178(3):1498-504. doi: 10.4049/jimmunol.178.3.1498. J Immunol. 2007. PMID: 17237398 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials
Miscellaneous